TNDM TANDEM DIABETES CARE INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1438133 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.8%
TTM net income YoY75.8%
TTM EPS YoY76.4%
Revenue 3-yr CAGR11.7%
Net income 3-yr CAGR—
Margins
Gross margin56.6%
Operating margin-2.4%
Net margin-4.6%
FCF margin-3.4%
EBITDA margin-0.7%
Returns
ROE-36.7%
ROA-4.8%
ROIC (approx.)-3.9%
Asset turnover1.06x
Leverage & solvency
Liabilities / assets88.3%
Debt / equity4.47x
Current ratio3.21x
Interest coverage-2.80x
Cash quality & payout
Operating cash flow / net income0.30x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue2.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.01B | $940.20M | $747.72M | $801.22M | $702.80M |
| Cost of revenue | $468.72M | $450.63M | $380.03M | $388.23M | $326.58M |
| Gross profit | $546.01M | $489.57M | $367.69M | $412.99M | $376.21M |
| R&D expense | $193.11M | $198.88M | $169.67M | $139.11M | $92.05M |
| SG&A expense | $444.99M | $389.82M | $352.50M | $335.68M | $261.51M |
| Operating income | -$187.26M | -$99.13M | -$233.23M | -$92.85M | $22.65M |
| Interest expense | $7.91M | $7.42M | $9.88M | $6.21M | — |
| Pretax income | -$200.27M | -$91.87M | -$220.25M | -$92.85M | $15.90M |
| Income tax | $4.44M | $4.16M | $2.36M | $1.74M | $335,000 |
| Net income | -$204.71M | -$96.03M | -$222.61M | -$94.59M | $15.57M |
| EBITDA | -$169.59M | -$82.52M | -$217.51M | -$78.52M | $36.50M |
| EPS (basic) | -3.04 | -1.47 | -3.43 | -1.47 | 0.25 |
| EPS (diluted) | -3.04 | -1.47 | -3.43 | -1.47 | 0.24 |
| Weighted avg. shares (diluted) | 67.28M | 65.45M | 64.97M | 64.15M | 64.35M |
| Balance sheet | |||||
| Cash & equivalents | $90.63M | $69.23M | $58.87M | $172.52M | $71.18M |
| Short-term investments | $202.03M | $369.10M | $409.04M | $444.38M | $552.63M |
| Receivables | $165.49M | $114.58M | $105.56M | $114.72M | $110.72M |
| Inventory | $128.77M | $149.61M | $157.94M | $111.12M | $68.55M |
| Current assets | $618.14M | $724.49M | $747.99M | $849.98M | $811.52M |
| PP&E, net | $83.58M | $78.15M | $76.54M | $68.55M | $50.39M |
| Intangibles | $11.72M | $925,000 | $2.78M | $4.63M | $6.64M |
| Total assets | $881.11M | $967.66M | $952.66M | $1.05B | $905.14M |
| Current liabilities | $242.72M | $247.05M | $195.26M | $165.29M | $131.86M |
| Short-term debt | — | $40.67M | $0 | — | — |
| Long-term debt | $310.04M | $308.27M | $285.04M | — | — |
| Total debt | $310.04M | $348.94M | $285.04M | — | — |
| Total liabilities | $725.94M | $704.56M | $639.03M | $612.84M | $472.02M |
| Shareholders' equity | $155.17M | $263.10M | $313.63M | $439.95M | $433.11M |
| Net debt | $219.40M | $279.70M | $226.17M | — | — |
| Shares outstanding | 68.29M | 66.26M | 65.55M | 64.51M | 63.83M |
| Cash flow statement | |||||
| Operating cash flow | -$9.72M | $24.23M | -$31.81M | $50.46M | $111.36M |
| Capital expenditure | $19.95M | $19.23M | $26.80M | $34.10M | $14.18M |
| Free cash flow | -$29.67M | $4.99M | -$58.61M | $16.37M | $97.18M |
| Investing cash flow | $72.88M | -$23.48M | -$85.74M | $33.17M | -$186.88M |
| Financing cash flow | -$43.37M | $8.37M | $4.11M | $16.88M | $51.93M |
| Depreciation & amortization | $17.67M | $16.61M | $15.71M | $14.33M | $13.85M |
| Stock-based compensation | $92.38M | $101.38M | $88.08M | $84.92M | $60.75M |
| Share buybacks | $0 | $30.00M | $0 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.